EUVIMEDOpdag EUVIMED
Multizentrische StudieBeobachtungsstudieOpen access

Therapies Used by Children With Primary Ciliary Dyskinesia: A Natural History Study

Robert A Gardner, Thomas W Ferkol, Stephanie D Davis, Margaret Rosenfeld, Scott D Sagel, Sharon D Dell, Carlos E Milla, Lang Li, Feng-Chang Lin, Kelli M Sullivan, Maimoona A Zariwala, Michael R Knowles and 2 more

Pediatric Pulmonology · 2025

DOI: 10.1002/ppul.27412 ↗

At a glance

Multizentrische Studie in Pediatric Pulmonology, 2025. Written by Robert A Gardner and 13 co-authors. Institution: Department of Pediatrics, Levine Children's Hospital, Wake Forest University School of Medicine, Charlotte, North Carolina, USA. Major MEDLINE topics: Anti-Bacterial Agents, Kartagener Syndrome. Cited 11 times so far (Crossref); 30 references. The full text is freely available in PubMed Central. Funded by: NHGRI NIH HHS, NCATS NIH HHS, Funding support for research was provided by US NIH/ORDR/NCATS/NHLBI grant U54HL096458; NIH/NCATS Colorado CTSA Grant UM1TR004399; US NIH/NHLBI grant R01HL0717….

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

Primary ciliary dyskinesia (PCD) management has not been systematically evaluated and is largely empirical.

Methods

Pediatric participants with PCD were enrolled in a prospective, longitudinal, multicenter, observational study. Therapies were recorded at annual visits and categorized by type. Age‐related trends in prevalence of therapies were described by serial cross‐sectional analyses. Generalized estimating equations analyzed covariates affecting prevalence of certain therapies and whether these covariates impacted oral antibiotic courses.

Results

A total of 137 participants completed 897 visits over 13 years. All but one received ≥ 1 antibiotic courses during study participation, most often cephalosporins (74%) or amoxicillin‐clavulanate (73%). Thirty‐one percent reported chronic azithromycin use. Per participant, there was an average of 2.3 (SD = 2.2) oral antibiotic courses annually. The rate of reported antibiotic courses at the 6 United States sites was 2.6 times higher compared to the Canadian site ( p < 0.001). As patients got older, they were more likely to report use of amoxicillin‐clavulanate ( p < 0.001), chronic azithromycin ( p < 0.001), fluroquinolones ( p < 0.001), inhaled steroids with long‐acting beta‐agonists ( p = 0.010), and hypertonic saline ( p < 0.001). Compared to outer dynein arm defects, those with inner dynein arm/microtubular disorganization defects reported increased use of chronic azithromycin ( p = 0.011) and inhaled steroids ( p = 0.015).

Discussion

Older participants and those with inner dynein arm/microtubular disorganization defects reported more therapies likely due to disease progression and more severe phenotypes, respectively. We report that a wide range of therapies are used in PCD without disease‐specific studies defining benefits and risks.

Subjects

MeSH terms (MEDLINE)

Anti-Bacterial AgentsKartagener SyndromeHumansMaleFemaleChildProspective StudiesChild, PreschoolAdolescentAzithromycinLongitudinal StudiesCross-Sectional StudiesInfantUnited StatesCanadaAmoxicillin-Potassium Clavulanate CombinationCephalosporins

Author keywords

natural historyprimary ciliary dyskinesiatherapy

Substances

Anti-Bacterial AgentsAzithromycinAmoxicillin-Potassium Clavulanate CombinationCephalosporins

Authors and institutions

  • Department of Pediatrics, Levine Children's Hospital, Wake Forest University School of Medicine, Charlotte, North Carolina, USA.
  • Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Marsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Department of Pediatrics, University of Washington, Seattle, Washington State, USA.
  • Department of Pediatrics, University of Colorado, Aurora, Colorado, USA.
  • Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.

Funding

  • NHGRI NIH HHS
  • NCATS NIH HHS
  • Funding support for research was provided by US NIH/ORDR/NCATS/NHLBI grant U54HL096458; NIH/NCATS Colorado CTSA Grant UM1TR004399; US NIH/NHLBI grant R01HL0717…
  • NHLBI NIH HHS
  • National Center for Advancing Translational Sciences

Cite

APA

Gardner, R. A., Ferkol, T. W., Davis, S. D., Rosenfeld, M., Sagel, S. D., Dell, S. D., Milla, C. E., Li, L., Lin, F. C., Sullivan, K. M., Zariwala, M. A., Knowles, M. R., Leigh, M. W., & Genetic Disorders of Mucociliary Clearance Consortium (2025). Therapies Used by Children With Primary Ciliary Dyskinesia: A Natural History Study. Pediatric Pulmonology. https://doi.org/10.1002/ppul.27412

Vancouver

Gardner RA, Ferkol TW, Davis SD, Rosenfeld M, Sagel SD, Dell SD, et al. Therapies Used by Children With Primary Ciliary Dyskinesia: A Natural History Study. Pediatric Pulmonology. 2025. doi:10.1002/ppul.27412

BibTeX
@article{Gardner2025,
  author = {Gardner, Robert A and Ferkol, Thomas W and Davis, Stephanie D and Rosenfeld, Margaret and Sagel, Scott D and Dell, Sharon D and Milla, Carlos E and Li, Lang and Lin, Feng-Chang and Sullivan, Kelli M and Zariwala, Maimoona A and Knowles, Michael R and Leigh, Margaret W and Genetic Disorders of Mucociliary Clearance Consortium, Genetic Disorders of Mucociliary Clearance Consortium},
  title = {Therapies Used by Children With Primary Ciliary Dyskinesia: A Natural History Study},
  journal = {Pediatric Pulmonology},
  year = {2025},
  doi = {10.1002/ppul.27412}
}
Start for free →